Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Down 15.5% in January

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the recipient of a large decrease in short interest in January. As of January 31st, there was short interest totalling 2,720,000 shares, a decrease of 15.5% from the January 15th total of 3,220,000 shares. Based on an average trading volume of 477,000 shares, the short-interest ratio is currently 5.7 days. Approximately 24.2% of the shares of the company are short sold.

Institutional Investors Weigh In On Jasper Therapeutics

Several institutional investors have recently modified their holdings of JSPR. Braidwell LP acquired a new position in shares of Jasper Therapeutics in the third quarter valued at approximately $9,091,000. Boxer Capital Management LLC bought a new stake in shares of Jasper Therapeutics in the fourth quarter worth $7,483,000. Integral Health Asset Management LLC raised its position in Jasper Therapeutics by 85.7% during the fourth quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $13,897,000 after acquiring an additional 300,000 shares in the last quarter. Ally Bridge Group NY LLC raised its position in shares of Jasper Therapeutics by 82.7% in the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after purchasing an additional 180,852 shares during the period. Finally, Soleus Capital Management L.P. raised its position in shares of Jasper Therapeutics by 11.2% in the fourth quarter. Soleus Capital Management L.P. now owns 1,494,420 shares of the company’s stock valued at $31,951,000 after purchasing an additional 150,755 shares during the period. Institutional investors and hedge funds own 79.85% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Royal Bank of Canada cut their price target on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a report on Thursday, January 9th. JMP Securities reaffirmed a “market outperform” rating and issued a $70.00 price target on shares of Jasper Therapeutics in a report on Monday, January 6th. UBS Group assumed coverage on Jasper Therapeutics in a research report on Thursday. They set a “buy” rating and a $38.00 target price for the company. BMO Capital Markets began coverage on Jasper Therapeutics in a research report on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target on the stock. Finally, HC Wainwright cut their price target on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating for the company in a report on Friday, January 10th. Eleven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $64.44.

Jasper Therapeutics Trading Down 1.9 %

Shares of NASDAQ:JSPR traded down $0.12 during trading on Monday, hitting $6.08. 477,987 shares of the company’s stock were exchanged, compared to its average volume of 671,338. Jasper Therapeutics has a 1-year low of $4.55 and a 1-year high of $31.01. The firm has a 50-day moving average price of $12.46 and a two-hundred day moving average price of $17.43. The firm has a market cap of $91.21 million, a P/E ratio of -1.28 and a beta of 2.11.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.